Esperion Therapeutics (ESPR) Short Interest Ratio & Short Volume $1.05 -0.01 (-0.94%) Closing price 04:00 PM EasternExtended Trading$1.06 +0.00 (+0.48%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Esperion Therapeutics Short Interest DataEsperion Therapeutics (ESPR) has a short interest of 28.90 million shares, representing 14.87% of the float (the number of shares available for trading by the public). This marks a -0.82% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.8, indicating that it would take 6.8 days of the average trading volume of 5.67 million shares to cover all short positions.Current Short Interest28,900,000 sharesPrevious Short Interest29,140,000 sharesChange Vs. Previous Month-0.82%Dollar Volume Sold Short$43.35 millionShort Interest Ratio6.8 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares197,849,000 sharesFloat Size194,370,000 sharesShort Percent of Float14.87%Today's Trading Volume10,563,602 sharesAverage Trading Volume5,666,920 sharesToday's Volume Vs. Average186% Short Selling Esperion Therapeutics? Sign up to receive the latest short interest report for Esperion Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartESPR Short Interest Over TimeESPR Days to Cover Over TimeESPR Percentage of Float Shorted Over Time Remove Ads Esperion Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202528,900,000 shares $43.35 million -0.8%14.9%6.8 $1.50 2/28/202529,140,000 shares $49.54 million +3.7%14.9%5.4 $1.70 2/15/202528,100,000 shares $52.27 million -10.1%14.4%5.1 $1.86 1/31/202531,240,000 shares $55.92 million -8.1%16.0%5 $1.79 1/15/202533,980,000 shares $75.10 million +5.0%17.4%5.6 $2.21 12/31/202432,350,000 shares $71.17 million +27.0%16.6%5.7 $2.20 12/15/202425,470,000 shares $57.31 million -16.5%13.1%4.6 $2.25 11/30/202430,490,000 shares $85.37 million -2.4%15.6%6.7 $2.80 11/15/202431,250,000 shares $66.25 million -6.6%16.0%8.2 $2.12 10/31/202433,460,000 shares $68.26 million -5.5%17.2%8.8 $2.04 Get the Latest News and Ratings for ESPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/15/202435,390,000 shares $75.38 million -5.6%18.2%9.7 $2.13 9/30/202437,470,000 shares $61.83 million -1.6%19.3%9.3 $1.65 9/15/202438,090,000 shares $72.75 million -5.8%19.6%6.9 $1.91 8/31/202440,440,000 shares $74.01 million -3.1%20.8%6.4 $1.83 8/15/202441,730,000 shares $82.21 million +9.4%21.5%6 $1.97 7/31/202438,140,000 shares $88.10 million -3.3%22.2%5.1 $2.31 7/15/202439,420,000 shares $98.55 million +67.4%25.5%4.8 $2.50 6/30/202423,550,000 shares $52.28 million -5.4%15.2%2.8 $2.22 6/15/202424,890,000 shares $74.42 million +13.7%16.1%3 $2.99 5/31/202421,890,000 shares $47.28 million -12.1%14.2%2.8 $2.16 5/15/202424,910,000 shares $57.29 million +25.4%16.1%3.4 $2.30 4/30/202419,870,000 shares $39.14 million +6.8%11.8%2.9 $1.97 4/15/202418,600,000 shares $35.99 million -6.6%11.0%3 $1.94 3/31/202419,920,000 shares $53.39 million +12.7%11.8%3 $2.68 3/15/202417,670,000 shares $36.58 million +4.3%10.5%2.8 $2.07 2/29/202416,950,000 shares $42.54 million -8.7%10.0%2.8 $2.51 2/15/202418,570,000 shares $49.40 million -7.5%11.0%3 $2.66 1/31/202420,070,000 shares $42.95 million -0.6%11.9%3.3 $2.14 1/15/202420,200,000 shares $61.00 million +1.4%17.9%3.7 $3.02 12/31/202319,920,000 shares $59.56 million +9.2%17.7%4.3 $2.99 12/15/202318,240,000 shares $33.20 million +2.8%16.2%4.3 $1.82 11/30/202317,740,000 shares $23.59 million -3.1%15.7%4.6 $1.33 11/15/202318,310,000 shares $21.06 million +0.5%16.2%4.7 $1.15 10/31/202318,220,000 shares $15.10 million -5.2%17.2%4.8 $0.83 10/15/202319,220,000 shares $15.95 million -3.0%18.1%5 $0.83 9/30/202319,810,000 shares $19.41 million +20.4%18.7%5.5 $0.98 9/15/202316,460,000 shares $23.37 million +8.4%15.5%4.7 $1.42 8/31/202315,180,000 shares $24.29 million +8.5%14.3%4.8 $1.60 8/15/202313,990,000 shares $22.94 million +4.3%13.2%5 $1.64 7/31/202313,410,000 shares $21.05 million +2.9%12.7%4.9 $1.57Trump to unlock 15-figure fortune for America (May 3rd) ? (Ad)We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. But something even more spectacular is bound to happen. And those who know what to expect could make 7/15/202313,030,000 shares $18.76 million +4.2%13.9%5.4 $1.44 6/30/202312,510,000 shares $17.39 million -9.9%13.3%5.1 $1.39 6/15/202313,880,000 shares $19.02 million +3.8%14.8%5 $1.37 5/31/202313,370,000 shares $18.18 million -8.4%14.3%3.6 $1.36 5/15/202314,600,000 shares $24.82 million No Change15.6%3.5 $1.70 10/31/202214,030,000 shares $114.06 million +5.3%N/A11.6 $8.13 10/15/202213,330,000 shares $101.31 million +6.6%N/A11.5 $7.60 9/30/202212,500,000 shares $83.75 million -0.9%N/A12.1 $6.70 9/15/202212,610,000 shares $94.83 million -5.5%N/A12.6 $7.52 8/31/202213,350,000 shares $99.59 million +8.6%N/A13.9 $7.46 8/15/202212,290,000 shares $81.97 million -1.8%N/A13.7 $6.67 7/31/202212,520,000 shares $72.24 million +3.2%N/A12.9 $5.77 7/15/202212,130,000 shares $81.39 million +2.6%N/A11.8 $6.71 6/30/202211,820,000 shares $75.18 million +6.8%N/A10.2 $6.36 6/15/202211,070,000 shares $59.00 million -4.2%N/A9.1 $5.33 5/31/202211,560,000 shares $65.89 million +13.7%N/A8.7 $5.70 5/15/202210,170,000 shares $58.78 million +15.8%N/A7.3 $5.78 4/30/20228,780,000 shares $49.87 million +10.0%N/A6.4 $5.68 4/15/20227,980,000 shares $47.00 million +8.7%N/A6.3 $5.89 3/31/20227,340,000 shares $34.06 million +36.7%N/A0 $4.64 3/15/20225,370,000 shares $24.70 million +29.7%N/A4 $4.60 2/28/20224,140,000 shares $16.93 million +18.0%N/A2.7 $4.09 2/15/20223,510,000 shares $14.00 million +11.4%N/A1.6 $3.99 1/31/20223,150,000 shares $13.51 million -3.7%N/A1.4 $4.29 1/15/20223,270,000 shares $12.85 million -62.2%N/A1.5 $3.93 12/31/20218,650,000 shares $43.25 million +10.6%N/A3.9 $5.00 12/15/20217,820,000 shares $41.84 million -20.9%N/A3.8 $5.35 11/30/20219,880,000 shares $86.25 million +11.5%N/A5.2 $8.73 11/15/20218,860,000 shares $77.26 million -3.5%N/A8.1 $8.72 10/29/20219,180,000 shares $82.07 million +15.2%N/A9.5 $8.94 10/15/20217,970,000 shares $72.85 million +8.7%28.7%9.3 $9.14 9/30/20217,330,000 shares $88.33 million -10.0%26.4%9.7 $12.05 9/15/20218,140,000 shares $92.31 million +0.5%29.3%11.4 $11.34 8/31/20218,100,000 shares $105.46 million -7.1%29.2%14.1 $13.02 8/13/20218,720,000 shares $121.30 million -3.3%31.4%15.4 $13.91 7/30/20219,020,000 shares $138.82 million -5.1%32.5%14.5 $15.39 7/15/20219,500,000 shares $167.96 million +5.2%34.3%14.1 $17.68 6/30/20219,030,000 shares $190.98 million +0.9%32.6%13.7 $21.15 6/15/20218,950,000 shares $221.96 million -0.4%32.3%14.2 $24.80 5/28/20218,990,000 shares $178.99 million -1.5%32.4%13.8 $19.91 5/14/20219,130,000 shares $204.51 million -5.8%N/A13.4 $22.40 4/30/20219,690,000 shares $264.63 million -0.8%40.8%14.1 $27.31 4/15/20219,770,000 shares $265.26 million +3.3%N/A14 $27.15 3/31/20219,460,000 shares $259.58 million -3.1%N/A12.1 $27.44 3/15/20219,760,000 shares $296.12 million -3.5%N/A11.7 $30.34 2/26/202110,110,000 shares $279.84 million +5.9%N/A12.2 $27.68 2/12/20219,550,000 shares $293.57 million -5.8%35.5%11.7 $30.74 1/29/202110,140,000 shares $325.70 million -8.5%37.7%12.3 $32.12 1/15/202111,080,000 shares $296.39 million +2.8%N/A12.9 $26.75 12/31/202010,780,000 shares $303.46 million +6.5%N/A15.7 $28.15Trump to unlock 15-figure fortune for America (May 3rd) ? (Ad)We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. But something even more spectacular is bound to happen. And those who know what to expect could make 12/15/202010,120,000 shares $299.35 million +3.5%44.0%15.5 $29.58 11/30/20209,780,000 shares $264.26 million +0.9%42.5%16 $27.02 11/15/20209,690,000 shares $278.01 million -3.7%42.1%15.2 $28.69 10/30/202010,060,000 shares $315.48 million -0.7%43.7%16.3 $31.36 10/15/202010,130,000 shares $342.19 million -9.1%N/A17.5 $33.78 9/30/202011,140,000 shares $414.07 million -0.3%N/A18.6 $37.17 9/15/202011,170,000 shares $414.74 million -3.5%N/A18 $37.13 8/31/202011,570,000 shares $417.68 million +5.1%N/A17.6 $36.10 8/14/202011,010,000 shares $361.24 million +1.2%40.9%16.2 $32.81 7/31/202010,880,000 shares $409.41 million +3.8%40.7%15.8 $37.63 7/15/202010,480,000 shares $496.96 million +3.5%39.2%16.3 $47.42 6/30/202010,130,000 shares $482.59 million +8.1%37.9%15.4 $47.64 6/15/20209,370,000 shares $411.81 million +15.4%35.1%13.6 $43.95 5/29/20208,120,000 shares $332.43 million -2.8%30.4%10.4 $40.94 5/15/20208,350,000 shares $372.58 million +7.6%31.2%9.9 $44.62 4/30/20207,760,000 shares $307.30 million +2.0%29.0%8.2 $39.60 4/15/20207,610,000 shares $261.94 million +8.6%28.5%8.2 $34.42 ESPR Short Interest - Frequently Asked Questions What is Esperion Therapeutics' current short interest? Short interest is the volume of Esperion Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 28,900,000 shares of ESPR short. 14.87% of Esperion Therapeutics' shares are currently sold short. Learn More on Esperion Therapeutics' current short interest. What is a good short interest ratio for Esperion Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ESPR shares currently have a short interest ratio of 7.0. Learn More on Esperion Therapeutics's short interest ratio. Which institutional investors are shorting Esperion Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Esperion Therapeutics: GTS Securities LLC, Wolverine Trading LLC, Squarepoint Ops LLC, Group One Trading LLC, Citadel Advisors LLC, Jane Street Group LLC, Concourse Financial Group Securities Inc., Walleye Trading LLC, Walleye Capital LLC, and Bank of Montreal Can. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Esperion Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 14.87% of Esperion Therapeutics' floating shares are currently sold short. Is Esperion Therapeutics' short interest increasing or decreasing? Esperion Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 28,900,000 shares, a decline of 0.8% from the previous total of 29,140,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Esperion Therapeutics' float size? Esperion Therapeutics currently has issued a total of 197,849,000 shares. Some of Esperion Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Esperion Therapeutics currently has a public float of 194,370,000 shares. How does Esperion Therapeutics' short interest compare to its competitors? 14.87% of Esperion Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Esperion Therapeutics: Adaptive Biotechnologies Co. (6.86%), Aurinia Pharmaceuticals Inc. (9.37%), Iovance Biotherapeutics, Inc. (25.34%), 89bio, Inc. (10.67%), Syndax Pharmaceuticals, Inc. (22.99%), Mineralys Therapeutics, Inc. (6.00%), Structure Therapeutics Inc. (12.92%), Spyre Therapeutics, Inc. (21.06%), Enliven Therapeutics, Inc. (23.17%), Collegium Pharmaceutical, Inc. (17.42%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), Strategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Esperion Therapeutics stock? Short selling ESPR is an investing strategy that aims to generate trading profit from Esperion Therapeutics as its price is falling. ESPR shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Esperion Therapeutics? A short squeeze for Esperion Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ESPR, which in turn drives the price of the stock up even further. How often is Esperion Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ESPR, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies Adaptive Biotechnologies Short Squeeze Aurinia Pharmaceuticals Short Squeeze Iovance Biotherapeutics Short Squeeze 89bio Short Squeeze Syndax Pharmaceuticals Short Squeeze Mineralys Therapeutics Short Squeeze Structure Therapeutics Short Squeeze Spyre Therapeutics Short Squeeze Enliven Therapeutics Short Squeeze Collegium Pharmaceutical Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ESPR) was last updated on 4/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESPR Stock Free ESPR Stock Alerts